Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8IV08
UPID:
PLD3_HUMAN
Alternative names:
Choline phosphatase 3; HindIII K4L homolog; Hu-K4; Phosphatidylcholine-hydrolyzing phospholipase D3; Phospholipase D3
Alternative UPACC:
Q8IV08; Q92853; Q9BW87
Background:
5'-3' exonuclease PLD3, also known as Phospholipase D3, plays a crucial role in DNA repair by digesting single-stranded DNA. It regulates inflammatory responses and is pivotal in myotube formation, lysosomal homeostasis, and endosomal protein sorting. Its alternative names include Choline phosphatase 3 and Phosphatidylcholine-hydrolyzing phospholipase D3.
Therapeutic significance:
PLD3's involvement in Spinocerebellar ataxia 46 highlights its potential as a therapeutic target. Although evidence is limited, understanding PLD3's role could open doors to novel treatments for neurodegenerative disorders.